Functional neuroendocrine tumors are often low-grade malignant neoplasms that can be cured by surgery if detected early, and such detection may in turn be accelerated by the recognition of neuropeptide hypersecretion syndromes. Uniquely, however, relief of peptic symptoms induced by hypergastrinemia is now available from acid-suppressive drugs such as proton-pump inhibitors (PPIs). Here we describe a clinical case in which time to diagnosis from the onset of peptic symptoms was delayed more than 10 years, in part reflecting symptom masking by continuous prescription of the PPI omeprazole. We propose diagnostic criteria for this under-recognized new clinical syndrome, and recommend that physicians routinely measure serum gastrin levels in persistent cases of PPI-dependent dyspepsia unassociated with H. pylori. © 2009 Arányi Lajos Foundation.
CITATION STYLE
Wong, H., Yau, T., Chan, P., Ng, I. O. L., Chan, G., Hui, P., … Epstein, R. J. (2010). PPI-delayed diagnosis of gastrinoma: Oncologic victim of pharmacologic success. Pathology and Oncology Research, 16(1), 87–91. https://doi.org/10.1007/s12253-009-9192-7
Mendeley helps you to discover research relevant for your work.